TY - JOUR
T1 - Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group
AU - Filosto, Massimiliano
AU - Cotti Piccinelli, Stefano
AU - Ravaglia, Sabrina
AU - Servidei, Serenella
AU - Moggio, Maurizio
AU - Musumeci, Olimpia
AU - Donati, Maria Alice
AU - Pegoraro, Elena
AU - Di Muzio, Antonio
AU - Maggi, Lorenzo
AU - Tonin, Paola
AU - Marrosu, Gianni
AU - Sancricca, Cristina
AU - Lerario, Alberto
AU - Sacchini, Michele
AU - Semplicini, Claudio
AU - Bozzoni, Virginia
AU - Telese, Roberta
AU - Bonanno, Silvia
AU - Piras, Rachele
AU - Maioli, Maria Antonietta
AU - Ricci, Giulia
AU - Vercelli, Liliana
AU - Galvagni, Anna
AU - Gallo Cassarino, Serena
AU - Caria, Filomena
AU - Mongini, Tiziana
AU - Siciliano, Gabriele
AU - Padovani, Alessandro
AU - Toscano, Antonio
PY - 2019
Y1 - 2019
N2 - Introduction: Patients with late-onset Pompe disease (LOPD) receiving enzyme replacement therapy (ERT) may develop IgG antibodies against alglucosidase alpha (anti-rhGAA) in the first 3 months of treatment. The exact role of these antibodies in modulating efficacy of ERT in this group of patients is still not fully understood. To assess whether anti rh-GAA antibodies interfere with ERT efficacy, we studied a large Italian cohort of LOPD patients. Methods: We analyzed clinical findings and performed serial measurements of IgG anti rh-GAA antibody titers from 64 LOPD patients treated with ERT. The first examination (T0) was completed on average at 17.56 months after starting ERT, while the follow-up (T1) was collected on average at 38.5 months. Differences in T0–T1 delta of the six-minute walking test (6MWT), MRC sum score (MRC), gait, stairs and chair performance (GSGC) and forced vital capacity (FVC) were considered and then related to the antibody titers. Results: Almost 22% of the patients never developed antibodies against GAA, while 78.1% had a positive titer (31.2% patients developed a low titer, 43.8% a medium titer and 3.1% a high titer). No statistical significance was found in relating the T0–T1 delta differences and antibody titers, except for MRC sum score values in a subgroup of patients treated < 36 months, in which those with a null antibody titer showed a greater clinical improvement than patients with a positive titer. Conclusion: Our results confirm that in a large cohort of LOPD patients, anti rh-GAA antibody generation did not significantly affect either clinical outcome or ERT efficacy. However, in the first 36 months of treatment, a possible interference of low-medium antibody titers with the clinical status could be present. Therefore, a careful and regular evaluation of antibody titers, especially in cases with evidence of clinical decline despite ERT, should be performed.
AB - Introduction: Patients with late-onset Pompe disease (LOPD) receiving enzyme replacement therapy (ERT) may develop IgG antibodies against alglucosidase alpha (anti-rhGAA) in the first 3 months of treatment. The exact role of these antibodies in modulating efficacy of ERT in this group of patients is still not fully understood. To assess whether anti rh-GAA antibodies interfere with ERT efficacy, we studied a large Italian cohort of LOPD patients. Methods: We analyzed clinical findings and performed serial measurements of IgG anti rh-GAA antibody titers from 64 LOPD patients treated with ERT. The first examination (T0) was completed on average at 17.56 months after starting ERT, while the follow-up (T1) was collected on average at 38.5 months. Differences in T0–T1 delta of the six-minute walking test (6MWT), MRC sum score (MRC), gait, stairs and chair performance (GSGC) and forced vital capacity (FVC) were considered and then related to the antibody titers. Results: Almost 22% of the patients never developed antibodies against GAA, while 78.1% had a positive titer (31.2% patients developed a low titer, 43.8% a medium titer and 3.1% a high titer). No statistical significance was found in relating the T0–T1 delta differences and antibody titers, except for MRC sum score values in a subgroup of patients treated < 36 months, in which those with a null antibody titer showed a greater clinical improvement than patients with a positive titer. Conclusion: Our results confirm that in a large cohort of LOPD patients, anti rh-GAA antibody generation did not significantly affect either clinical outcome or ERT efficacy. However, in the first 36 months of treatment, a possible interference of low-medium antibody titers with the clinical status could be present. Therefore, a careful and regular evaluation of antibody titers, especially in cases with evidence of clinical decline despite ERT, should be performed.
KW - Anti rh-GAA antibodies
KW - GSD II
KW - Glycogen storage diseases II
KW - LOPD
KW - Pharmacology (medical)
KW - Pompe disease
KW - Anti rh-GAA antibodies
KW - GSD II
KW - Glycogen storage diseases II
KW - LOPD
KW - Pharmacology (medical)
KW - Pompe disease
UR - http://hdl.handle.net/10807/133231
UR - http://www.springer.com/springer+healthcare/journal/12325
U2 - 10.1007/s12325-019-00926-5
DO - 10.1007/s12325-019-00926-5
M3 - Article
SN - 0741-238X
VL - 2019
SP - N/A-N/A
JO - Advances in Therapy
JF - Advances in Therapy
ER -